Kezar Life Sciences...Reports Fourth Quarter and Year End 2024 Financial Results (GlobeNewswire) - Mar 25, 2025 - "Research and development (R&D) expenses for the fourth quarter of 2024 decreased by $6.6 million to $16.0 million, compared to $22.6 million in the fourth quarter of 2023. Full year R&D expenses decreased by $20.0 million to $65.7 million in 2024, compared to $85.7 million in 2023....The decrease was partially offset by the increased clinical trial costs related to the PALIZADE and PORTOLA trials."
Commercial • Autoimmune Hepatitis • Lupus Nephritis
|